1. miR-155 levels are significantly and increasingly overexpressed as normal B-cells progress to MBL and to CLL.
INTRODUCTION
Discoveries over the past decade have shown that non-coding RNAs-RNAs that do not code for proteins 1 -play a central role in the molecular pathogenesis of chronic lymphocytic leukemia (CLL) 2 . In particular, small microRNAs (miRNAs) regulate gene expression by targeting messenger RNA (mRNA) for degradation or translational repression, and are involved at the posttranscriptional level in many physiologic and pathologic processes 3 . Complex interaction networks composed of coding and non-coding genes have been found to be involved in the pathogenetic mechanism of CLL, influencing the natural history of the disease. For example, a miRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome 4 , and multiple defects in the components of the TP53 pathway are involved in fludarabinerefractory CLL 5 .
Although these findings expand our understanding of the molecular pathology of CLL, the molecular mechanisms related to the earliest stages of CLL development, the transformation of normal B-cells to malignant B-cells, and the progression of this disease are still unknown.
Over the past several years, it has become apparent/evident that monoclonal B-cell populations with an aberrant immunophenotype similar to that of CLL can be detected in up to 3% of individuals who otherwise lack signs and symptoms of CLL 6 . Monoclonal B-cell populations may also be identified in asymptomatic individuals undergoing evaluation for lymphocytosis (absolute lymphocyte count is 3-5 × 10 6 /μl), and these patients are designated/labeled as having "clinical" or "high count monoclonal B-cell lymphocytosis (MBL)" 7 . MBL clones may demonstrate the common recurrent cytogenetic abnormalities associated with typical CLL and are more common in elderly adults and in individuals with a family history of CLL 8 . Despite the presence of an aberrant immunophenotype and cytogenetic abnormalities, progression to CLL among individuals with clinical MBL is very low (1-2% per year) 8, 9 , and the risk of developing CLL among individuals with population-screening MBL may not differ from that of the general population. Furthermore, the events that initiate progression from clinical MBL to CLL remain
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Effective treatment options are available for patients with CLL, such as the chemoimmunotherapy combination of fludarabine, cyclophosphamide, and rituximab (FCR).
These types of treatments can induce remissions in up to 90% of patients 10 . However, some patients do not respond to upfront chemoimmunotherapy combinations or they rapidly develop resistance to the treatment. Additionally, the durations of the remission vary 10, 11 . Although 17p deletion defects or p53 mutations account for perhaps 30-40% of all cases of CLL with primary resistance to chemoimmunotherapy, the remainder of cases of chemoimmunotherapy-resistant CLL have unknown resistance mechanisms 12 . Markers such as immunoglobulin heavy chain variable (IgHV) status and beta-2-microglobulin (B2M) have been shown to predict treatmentfree intervals, remission durations and survival, but they have limited ability to predict clinical response 13 . However, we have previously found that miRNAs (such as miR-21) can be used to stratify patients with CLL in terms of their risk for disease progression 14 . In this study, on the basis of the important role of miRNAs in CLL initiation and progression 2 , we hypothesized that some miRNAs might be involved in the transition from clinical MBL to CLL and that these miRNAs may also predict response to therapy in patients with CLL. patients who received treatment with lenalidomide at MD Anderson (group E). Group E was added to our study to prevent treatment bias. Of note, both MD Anderson and UCSD plasma samples were stored in the same centralized facility in San Diego, and therefore were maintained in the same conditions. Patient characteristics are summarized in Table 2 and Table S2 . All patients from these clinical trials provided informed consent per institutional guidelines, and this study was conducted in accordance with the Declaration of Helsinki.
MATERIALS and METHODS

Cell samples from normal individuals, individuals with MBL and patients with CLL
All patients had a confirmed diagnosis of CLL based on immunophenotypic features and were staged according to the Rai classification 21, 22 . Baseline B2M levels, IgHV gene mutation status, and ZAP70 expression levels were assessed either by immunohistochemistry or flow cytometry, prior to initiation of therapy in most patients ( Table S3 . Expression levels for 5s ribosomal RNA (5s rRNA) were similar for all groups of plasma samples, and this was measured using the SYBR Green method (Bio-Rad SsoFast) (Supplemental Results and Figure S1 ). Reverse transcription reaction was performed on 10 ng total RNA of each patient sample with random hexamers using SuperScript III First-Strand Synthesis System (Invitrogen), according to the manufacturer's instructions. Real-time qPCR analysis was performed using the gene-specific Taqman assay (primers and probes; Applied Biosystems) and SsoFast Probe Supermix (BioRad), according to the manufacturer's protocol.
RNA isolation from plasma, miRNA expression analysis, and normalizer identification
RNA isolation was performed on 100 µl of stored plasma collected on citrate using the Norgen kit (Norgen Biotek, Canada). miRNA expression was measured using the TaqMan miRNA qRT-PCR method and all reactions were run in duplicate. The expression of a miRNA relative to the endogenous control (miR-16) was determined using the 2 -ΔCt method. If expression values for the endogenous control or for a specific miRNA were not obtained after 35 cycles of amplification in 2 successive experiments in duplicate wells, then the specific values were considered to be unavailable. The miRNA expression values are shown in Table S4 . For accuracy and reproducibility, we performed miR-16 normalization on the same 384-well plate for each target miRNA amplified.
Microvesicle purification from individuals with MBL and patients with CLL
Microvesicles (MVs) were isolated from "platelet-free plasma" obtained from 1 individual with MBL, 1 patient with Rai stage 0 CLL, and 3 patients with CLL of higher stages as previously described 23, 24 . Purity of the MVs was determined by their binding ability to annexin V, and total
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Statistical analysis
All statistical analyses were performed in R (version 2.14.2). All tests were 2-sided and considered statistically significant at the 0.05 level. If the data were continuously numeric, the Shapiro-Wilk test was applied to determine whether data followed a normal distribution. The t test or analysis of variance followed by the post-hoc Tukey test (depending on the number of groups considered) was applied to normally distributed data; otherwise, the Mann-WhitneyWilcoxon test or Kruskal-Wallis test followed by a post hoc Nemenyi test was applied to assess the relationship between miRNA expression and response to treatment. The Pearson correlation test was applied to measure the strength of the linear association between the variables. The logrank test was employed to determine the relationship between miRNA expression and overall survival (OS; defined as the time from sample collection to death or last follow-up). The KaplanMeyer method was used to generate OS curves. Patients were grouped into percentiles according to miRNA expression, and the log-rank test was used to assess the relationship between miRNA expression and OS. The relationship between OS and covariates (miRNA expression levels and known prognostic factors or other clinical parameters such as clinical stage, B2M levels, IgHV mutation status, ZAP70 expression, and various FISH-detectable genetic mutations) was examined using a Cox proportional hazard model ( Table 3) . 28, 29 , and high levels of miR-21 have previously been found to be associated with shorter survival in patients with CLL 14 . Transgenic miR-21 mice develop B-cell leukemia 30 .
Finally, miR-155 is highly expressed in various types of B-cell malignancies, including CLL 24 , and increased levels are associated with poor prognosis 28 . Transgenic miR-155 mice develop a Bcell-type of leukemia 31 .
Expression of miR-155 in CD19 + B-cells from normal individuals, individuals with MBL,
and patients with CLL. We investigated the levels of these three miRNAs in B-cells from groups A and B ( Table 1) . We first tested various non-coding RNAs as normalizers, including U6 snRNA, U18 snRNA, U48 snRNA, 5S rRNA, and 18S rRNA. Out of these 5 genes, only 5S
rRNA showed constant expression in all 3 types of samples from both cohorts (Supplementary Figure 1) , and therefore we decided to use this as the reference gene, similar to another prior report 32 . In both training set (group A) and validation set (group B), miR-155 was significantly overexpressed in MBL when compared with normal B-cells, and was even more highly
For personal use only. on June 29, 2017 . by guest www.bloodjournal.org From overexpressed in CLL (Figure 1A and B) . This overexpression pattern was also observed when we compared MBL cells with CLL cells from Rai 0 patients, the earliest stage of CLL ( Figure   1C and D) . Although the other miRNAs (miR-15a/16-1 and miR-21), showed statistically significant differential expression among the samples, they either did not follow the pattern of consistently increasing with progressing stages or the changes were not fully reproducible between the training and validation cohorts (Supplementary Figure 2) .
We also examined the relationship between miR-155 expression levels and clinical characteristics of individuals with MBL and patients with CLL. We did not find a significant correlation between miR-155 expression levels and advanced Rai stage, IgVH mutation status, ZAP70 status, FISH abnormalities, or median time to treatment (data not shown). However, when we divided the MBL samples into sextiles according to the absolute lymphocyte count (ALC), miR-155 levels were significantly higher in samples with the highest ALC compared with samples that had the lowest ALC in both A and B groups (Supplementary Figure 3) . The lack of correlation between miR-155 and clinical signs of disease is consistent with, and supports the concept that alterations in miR-155 expression are potentially the earliest abnormalities and therefore occur before the transition from MBL to CLL, independently of other clinical and biological abnormalities. Since we previously observed that miR-21 expression levels were significantly increased in CLL patients with poor prognosis and that miR-21 predicted decreased OS, 14 we used miR-21 expression as a control for performing survival analysis. In the current study, we confirmed that CLL patients from groups A and B (n = 93) with high miR-21 levels (above the 44 th percentile) had significantly shorter OS compared to patients who showed low expression of miR-21 (Supplementary Figure 4) .
We next postulated that miRNAs exhibiting a consistent and steady variation in expression across the clinical spectrum of human B-cell transformation may have the greatest value as a biomarker. miRNAs are secreted by various cells, including malignant cells 33, 34 . We previously showed that the plasma of patients with CLL contains both platelet-derived and 
Relationship between plasma miR-155 levels and response to treatment and OS
We first measured the expression of miR-155 in plasma samples collected at the start of therapy from 143 patients with CLL who received initial treatment with FCR chemoimmunotherapy (group C, Table 2 ). Response data were available, and the long-term follow-up (median 83 months) allowed us to explore clinical correlations with pretreatment miR-155 levels. miR-155 expression did not correlate with disease stage, absolute leukocyte count, or tumor burden prior to initiation of treatment (data not shown). We found that the relative expression levels of miR-155 prior to therapy were significantly lower in patients who experienced CR than in those who experienced poorer treatment responses, either when compared with all groups together (NPR + PR + NR, P = 0.0103 by Wilcoxon test; Figure 2A ) or with individual groups (Figure 2B ). This pattern was not found for miR-21 amplified in the same experiment (Supplementary Table 4) . Furthermore, we found that patients with high miR-155 levels prior to treatment had significantly shorter OS than patients with lower levels of miR-155 (P = 0.012; Figure 3A and Table 3 ). This was also observed when the analyses were restricted to the 112 patients from group C with CR (Supplementary Figure 9) . We did not find significant differences in age between patients expressing high levels of miR-155 and those expressing low levels of miR-155 (P = 0.077, Mann-Whitney-Wilcoxon test). Other than a correlation between high relative expression levels of miR-155 (r = 0.30; P = 0.0003; Figure 3B ) and elevated B2M levels, no correlations were found between miR-155 relative expression levels and other prognostic factors included in Table 2 (data not shown). Interestingly, the OS disadvantage for patients expressing high levels of miR-155 prior to treatment with FCR was identified even when patients were stratified according to response to therapy. Table 3 ). When we compared miR-155 expression among groups with the individual FISH categories, significant difference was detected using the Wilcoxon rank-sum test (P = 0.021), with the highest levels in the 17p deletion category (Supplementary Figure 10) , further indirectly supporting the association with survival.
The ability of miR-155 to predict response to therapy was confirmed in a separate group of 31 patients treated with the FCR chemoimmunotherapy at time of recurrent disease (group D, Table 2 ). We confirmed that pretreatment relative miR-155 expression levels in plasma were significantly lower (P = 0.0202) in patients who experienced CR than in those who experienced poorer treatment response ( Figure 4A ). When we analyzed plasma samples collected prior to treatment with single agent lenalidomide of 54 patients (group E, Table 2 ) 37, 38 , we found that relative expression levels of miR-155 were also significantly lower (P = 0.0303) in patients who experienced CR than in patients who experienced other responses (Figure 4B) , confirming the findings observed in the other patient groups. These data validate the ability of miR-155 to predict response to treatment independently of the type of therapy administered. The use of plasma instead of malignant cells for miRNA profiling offers several advantages. First, plasma is easily accessible and performing RNA extraction on plasma samples for measurement of miRNAs is technically quick and easy to implement in CLIA-compliant laboratories specialized in assay development. Second, recent reports have proposed that miRNAs are hormones released by a donor cell and that miRNAs spread signals that influence cells located in other parts of the organism 31 . Indeed, we found that miR-155 was present in circulating plasma MVs purified from patients with CLL. Therefore, miRNA profiling in plasma could reflect more accurately the complex interrelationships that facilitate the proliferation of malignant B-cells 34 . In support of this, we observed in our previously published study 14 that the levels of miR-155 in cells of patients with CLL with 17p deletion or with normal FISH results and normal cytogenetic findings did not correlate with OS, meaning that the plasma pool of miR-often reduced during and after therapy, whereas plasma is likely to continue to reflect abnormal gene profiles at these times 33 . In line with this, a recent study showed that extracellular miRNAs are present in the plasma of patients with CLL at levels significantly different from healthy controls, with significant differences in miRNA expression observed between ZAP70-positive and ZAP70-negative patients. In addition, miRNA expression levels correlated reliably with the diagnosis-to-treatment time 39 . Expression of miR-155 in vitro was shown to significantly increase after stimulation of distinct toll-like receptors in CLL cells in which fludarabine treatment was less effective 40 . Of interest, although in the "paired" cell/plasma samples of CLL miR-16 varied according to 13q deletion status in B cells, we demonstrated that the gene can be used as a normalizer in plasma due to constant expression. This can be explained by the fact that multiple types of blood cells could secrete this miR-16 in addition to malignant cells 33, 34 .
DISCUSSION
In conclusion, our study identified miR-155 as a useful marker and highlights its potential Table 2 . Characteristics of patients with chronic lymphocytic leukemia (CLL) for which plasma was analyzed prior to initiation of therapy (n = 228). Table 3 . In A and B, the P values were calculated using the Kruskal-Wallis test. Table 4 . CR, complete response, NPR, nodular partial response, PR, partial response, and NR, no response. In B, the P value was calculated using the Kruskal-Wallis test. 
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Correlation between plasma levels of miR-155 and serum beta-2-microglobulin levels. 
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